Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 237,162,593 papers from all fields of science
Search
Sign In
Create Free Account
farletuzumab
Known as:
Fareletuzumab
A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity. Farletuzumab specifically targets at glycoprotein 3 (GP-3), a…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (1)
Antibodies, Monoclonal, Humanized
FOLR1 protein, human
NCIt Antineoplastic Agent Terminology
antigen binding
Narrower (1)
MORAb-003
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
FOLATE RECEPTOR-ALPHA AND THE EFFECT OF CHEMOTHERAPY ON EXPRESSION RATES IN OVARIAN CANCER
Lucia Marie Albertine
2019
Corpus ID: 143428695
BACKGROUND Folate receptor alpha (FR-α) has been identifi ed as a potential target in ovarian cancer for diagnostic and…
Expand
2018
2018
Effect of the tumor-shed antigen CA125 on humoral immune responses of IgG1, IgG3, and IgM-type antibodies.
J. Kline
2018
Corpus ID: 80193633
15Background: Human cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of CA125 on…
Expand
2017
2017
Abstract 644: CA125/MUC16 suppresses antibody-dependent cellular cytotoxicity of IgG1-based therapies via perturbation of antibody Fc-Receptor engagement on immune effector cells
J. Kline
,
Rina P. Kennedy
,
+7 authors
N. Nicolaides
2017
Corpus ID: 79486555
Background: Human cancers employ a number of mechanisms to evade host immune responses. Here we report the effects of the tumor…
Expand
Review
2013
Review
2013
Although ovarian cancer may spread to distant sites via the bloodstream and / or nodal system , most of the Overview of Ovarian Cancer
D. Armstrong
,
R. Coleman
,
R. Penson
2013
Corpus ID: 30827784
Ovarian cancer is a relatively infrequent malignancy, but it is the fifth leading cause of cancer-related mortality in American…
Expand
Review
2012
Review
2012
Abstract 1750: A phase 3 trial of weekly farletuzumab combined with carboplatin and taxane in subjects with platinum-sensitive ovarian cancer in first relapse
S. Weil
,
M. Jenkins
,
K. Hoffman
2012
Corpus ID: 72256851
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Background: Ovarian cancer is the leading cause of…
Expand
2012
2012
Co-administration d'éribuline et de farletuzumab pour le traitement du cancer du sein
J. Maltzman
2012
Corpus ID: 80202591
La presente invention concerne des methodes de traitement d'un sujet atteint d'un cancer du sein par l'administration (a) d…
Expand
2012
2012
Abstract 4411: Farletuzumab (mAb003), a neutralizing monoclonal antibody to folate receptor alpha, enhances paclitaxel efficacy in an ovarian cancer model
Christopher Maddage
,
K. Rybinski
,
Yuhong Zhou
,
L. Grasso
,
N. Nicolaides
,
Jianmin Lin
2012
Corpus ID: 73364833
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Farletuzumab, MORAb-003 is a humanized monoclonal…
Expand
2008
2008
Gateways to clinical trials.
A. Tomillero
,
M. A. Moral
Methods and Findings in Experimental and Clinical…
2008
Corpus ID: 26153196
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the…
Expand